Benign prostatic hyperplasia(BPH) and prostatitis are two common diseases in aging men. In recent years, the study of correlation between these two diseases has been paid more and more attention to. Some researchers presumed that inflammation is one of the most important causations of BPH, however, it is not profound enough on this etiologic hypothesis at present. The writer, on the base of his clinical experiences, dissertated the etiology of BPH, the pathologic figures of coexistence of BPH and prostatitis, and the presumption of inflammation promoting BPH on the molecular biology level. We hope our colleagues pay attention to this problem, and do more study on it.
Humans ; Male ; Prostatic Hyperplasia ; complications ; etiology ; Prostatitis ; complications ; etiology

With the development of living standard and the aging society, the incidences of metabolic syndrome and benign prostatic hyperplasia are getting higher and higher. Recent studies show that both metabolic syndrome and benign prostatic hyperplasia are associated with blood vessel injury, hyperinsulinemia and over-activity of the sympathetic nerve. This article presents an overview on the interaction of these two diseases.
Humans ; Hyperinsulinism ; Male ; Metabolic Syndrome ; complications ; Prostatic Hyperplasia ; complications

Benign prostate hyperplasia (BPH) and chronic prostatitis (CP) are common diseases in males, and BPH is often complicated by CP. This review focuses on the relationship of BPH with CP and their epidemiology, pathogenesis and clinical features. Patients with BPH or CP are more likely to be subjected to another disease. Inflammation may be involved in the development of BPH. Compared with simple BPH, patients with CP-complicated BPH have significantly higher scores on age, prostate weight, prostate volume, and IPSS. Some related therapies are also evaluated, such as selective use of the alpha1-receptor blocker, 5alpha-reductase inhibitor, antibiotics, ultrasound microbubble contrast agents, and so on.
Chronic Disease ; Humans ; Male ; Prostatic Hyperplasia ; complications ; Prostatitis ; complications

Prostatic diseases and erectile dysfunction (ED) are common diseases in urology and andrology. Basic and clinical studies have proved that there is a close relationship between the two. This article reviews the mechanism, diagnosis and treatment of ED caused by several prostatic diseases, such as acute prostatitis, chronic prostatitis, benign prostate hyperplasia and prostate cancer.
Chronic Disease ; Erectile Dysfunction ; diagnosis ; etiology ; therapy ; Humans ; Male ; Prostatic Diseases ; complications ; Prostatic Hyperplasia ; complications ; Prostatic Neoplasms ; complications ; Prostatitis ; complications

Diabetes Complications ; Diabetes Mellitus ; Humans ; Hypertension ; complications ; Male ; Prostatic Hyperplasia ; complications

Humans ; Male ; Prostatic Hyperplasia ; complications ; Quality of Life ; Urinary Bladder, Overactive ; complications

OBJECTIVETo explore the clinical characteristics of benign prostatic hyperplasia (BPH) complicated by chronic prostatitis (CP).

METHODSA total of 120 cases of BPH pathologically confirmed after transurethral resection of the prostate (TURP) were assigned to a BPH group (n=75) and a BPH + CP group (n=45) according to whether they were complicated by CP. The total prostatic volume (TPV) and PSA density (PSAD) were calculated and statistically analyzed based on the results of transrectal ultrasonography and f-PSA, t-PSA and f-PSA/t-PSA tests before surgery.

RESULTSThe BPH group showed a significantly upward tendency in f-PSA and t-PSA (P < 0.05) with the increase of age or prostate volume, but not significantly in PSAD and f-PSA/t-PSA (P > 0.05). In comparison, the BPH + CP group exhibited remarkable increases in f-PSA, t-PSA and PSAD (P < 0.05) but not in fPSA/t-PSA (P > 0.05). ROC curve analyses of various indexes showed the area under the curve to be 0.644, 0.628 and 0.624 for f-PSA, t-PSA and PSAD, respectively, all between 0.5 and 0.7.

CONCLUSIONBPH is frequently associated with CP. Clinically, high f-PSA, t-PSA and PSAD are important but not sure indicators of BPH complicated by CP.

Aged ; Chronic Disease ; Humans ; Male ; Prostatic Hyperplasia ; complications ; diagnosis ; Prostatitis ; complications ; diagnosis

PURPOSE: We compared the outcome of transurethral electro-vaporization of the prostate (TVP) with that of transurethral resection of the prostate (TURP) in patient with benign prostate hyperplasia (BPH). MATERIALS AND METHODS: Fifty-four patients with BPH were treated with TVP (Group I) and sixty-two with TURP (Group II). Patients were assessed at baseline for both safety and efficacy and in follow-up at 1 and 3 months. Efficacy parameters evaluated included American Urological Association (AUA) symptom score, peak urinary flow rate (Qmax) and post-void residual urine volume (ml). Safety parameters evaluated included incidence of side effects, operative time, postoperative catheterization time, change in hematocrit and serum sodium. RESULTS: The mean prostate size was 28.4+/-4.8gm in GroupI and 37.1+/-5.3gm in Group II. The mean operation time was shorter in Group I (48.2+/-10.5min) than in Group II (75.2+/-32.6min) (p<0.05). The change of hematocrit (%) was lower in Group I (from 40.2+/-4.1 to 38.7+/-4.1) than in Group II (from 40.3+/-3.8 to 34.9+/-5.5), (p<0.05). The mean catheterization time was 3.2+/-1.2 days and 4.9+/-1.9 days (p<0.05). The change of peak urinary flow rate, post-void residual urine volume, AUA symptom score, incidence of postoperative complications was not significantly different between each group. CONCLUSIONS: Although the TURP is the gold standard for the treatment of symptomatic BPH with high success rate, significant morbidities are associated with this procedure. Our early clinical experience highlights several advantages of electro-vaporization, particulary the low incidence of postoperative morbidity.
Catheterization ; Catheters ; Follow-Up Studies ; Hematocrit ; Humans ; Hyperplasia ; Incidence ; Operative Time ; Postoperative Complications ; Prostate* ; Prostatic Hyperplasia* ; Sodium ; Transurethral Resection of Prostate

This study evaluated the association of periurethral calcification (PUC) with uroflowmetric parameters and symptom severity in male patients with lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). The data were collected from a prospectively maintained database of 1321 men with LUTS of BPH who visited Chonnam National University Hospital (Gwang-ju, Korea) from January 2015 to December 2019. PUC severity and location were evaluated on the midsagittal plane during transrectal ultrasonography. Relationships among age, prostate-related parameters, International Prostate Symptom Score (IPSS), and uroflowmetric parameters were assessed. Among the 1321 patients in this study, 530 (40.1%) had PUC. Patients with PUC had significantly higher IPSS (mean ± standard deviation [s.d.]: 15.1 ± 8.7 vs 13.1 ± 7.9; P < 0.001) and lower peak flow rate (Qmax; mean ± s.d.: 12.4 ± 6.6 ml s^-1 vs 14.7 ± 13.3 ml s^-1; P < 0.001), compared with patients who did not have PUC. Analyses according to PUC severity revealed that patients with severe PUC had higher prostate-specific antigen (PSA) level (P = 0.009), higher total IPSS (P < 0.001), lower Qmax (P = 0.002), and smaller prostate volume (P < 0.001), compared with patients who had non-severe (mild or moderate) PUC. Multivariate analysis showed that distal PUC was independently associated with high total IPSS (P = 0.02), voiding symptom score (P = 0.04), and storage symptom score (P = 0.023), and low Qmax (P = 0.015). In conclusion, PUC was significantly associated with worse LUTS parameters in terms of IPSS and Qmax. Furthermore, distally located PUC was independently associated with worse LUTS of BPH in men.
Humans ; Male ; Prostatic Hyperplasia/diagnostic imaging* ; Prostate/diagnostic imaging* ; Clinical Relevance ; Hyperplasia ; Lower Urinary Tract Symptoms/complications* ; Calcinosis/diagnostic imaging*

A retrospective analysis of 108 patients who had undergone transurethral prostatectomy for benign prostatic hyperplasia between January 1988 and December 1992 was performed to evaluate risk factors influencing intraoperative and postoperative morbidity and mortality. Of 108 patients complications occurred in 32 cases, with the morbidity rate of 29.6% but no death occurred. The most common postoperative complication was bleeding in 9 cases(8.3%) followed by incontinence in 7 cases(6.5%), capsular perforation in 4 cases(3.7%), failure to void in 4 cases(3.7%) and urethral stricture in 4 cases(3.7%). Risk factors which increased the morbidity of transurethral prostatectomy were age greater than 75 years and the presence of associated medical disease(p<0.05) but a resection time of more than 90 minutes, weight of resected tissue more than 30 gram and amounts of irrigating solution of more than 20 L did not increase the postoperative morbidity significantly. In conclusion, meticulous preoperative and postoperative cares are necessary because poor general condition increase the postoperative complications and long-term, prospective randomized studies are required to evaluate risk factors influencing postoperative morbidity after transurethral prostatectomy.
Hemorrhage ; Humans ; Mortality ; Postoperative Complications ; Prostatic Hyperplasia* ; Retrospective Studies ; Risk Factors* ; Transurethral Resection of Prostate* ; Urethral Stricture